{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:55:24Z","timestamp":1784674524221,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00508-020-01802-x","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T15:03:10Z","timestamp":1611068590000},"page":"97-103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Higher serum uric acid is associated with higher risks of thrombosis and death in patients with primary myelofibrosis"],"prefix":"10.1007","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1372-2040","authenticated-orcid":false,"given":"Marko","family":"Lucijanic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Krecak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davor","family":"Galusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Sedinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hrvoje","family":"Holik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlatka","family":"Perisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Moric Peric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Zekanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tajana","family":"Stoos-Veic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlatko","family":"Pejsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajko","family":"Kusec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"issue":"20","key":"1802_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber\u00a0DA, Orazi\u00a0A, Hasserjian\u00a0R, et\u00a0al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"2","key":"1802_CR2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.leu.2404914","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi\u00a0G, Mesa\u00a0RA, Thiele\u00a0J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a\u00a0consensus statement from the international working group for myelofibrosis research and treatment. Leukemia. 2008;22(2):437\u20138.","journal-title":"Leukemia"},{"key":"1802_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22789","author":"F Courtier","year":"2019","unstructured":"Courtier\u00a0F, Garnier\u00a0S, Carbuccia\u00a0N, et\u00a0al. Targeted molecular characterization shows differences between primary and secondary myelofibrosis. Genes Chromosomes Cancer. 2019; https:\/\/doi.org\/10.1002\/gcc.22789.","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"1802_CR4","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1038\/leu.2017.169","volume":"31","author":"F Passamonti","year":"2017","unstructured":"Passamonti\u00a0F, Giorgino\u00a0T, Mora\u00a0B, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31(12):2726\u201331.","journal-title":"Leukemia"},{"key":"1802_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.01.017","author":"M Lucijanic","year":"2018","unstructured":"Lucijanic\u00a0M, Prka\u00a0Z, Pejsa\u00a0V, Stoos-Veic\u00a0T, Lucijanic\u00a0J, Kusec\u00a0R. Prognostic implications of low transferrin saturation in patients with primary myelofibrosis. Leuk Res. 2018; https:\/\/doi.org\/10.1016\/j.leukres.2018.01.017.","journal-title":"Leuk Res"},{"issue":"9","key":"1802_CR6","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti\u00a0F, Cervantes\u00a0F, Vannucchi\u00a0AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a\u00a0study by the IWG-MRT (international working group for myeloproliferative neoplasms research and treatment). Blood. 2010;115(9):1703\u20138.","journal-title":"Blood"},{"issue":"2","key":"1802_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","volume":"8","author":"T Barbui","year":"2018","unstructured":"Barbui\u00a0T, Thiele\u00a0J, Gisslinger\u00a0H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer\u00a0J. 2018;8(2):15.","journal-title":"Blood Cancer J"},{"issue":"10","key":"1802_CR8","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s00277-017-3099-2","volume":"96","author":"D Kc","year":"2017","unstructured":"Kc\u00a0D, Falchi\u00a0L, Verstovsek\u00a0S. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a\u00a0review. Ann Hematol. 2017;96(10):1595\u2013604.","journal-title":"Ann Hematol"},{"key":"1802_CR9","doi-asserted-by":"publisher","first-page":"12144","DOI":"10.1038\/srep12144","volume":"5","author":"W Lu","year":"2015","unstructured":"Lu\u00a0W, Xu\u00a0Y, Shao\u00a0X, et al. Uric acid produces an inflammatory response through activation of NF-kappaB in the hypothalamus: implications for the pathogenesis of metabolic disorders. Sci Rep. 2015;5:12144.","journal-title":"Sci Rep"},{"issue":"17","key":"1802_CR10","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra0800885","volume":"359","author":"DI Feig","year":"2008","unstructured":"Feig\u00a0DI, Kang\u00a0DH, Johnson\u00a0RJ. Uric acid and cardiovascular risk. N\u00a0Engl J Med. 2008;359(17):1811\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"1802_CR11","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/BOR.0b013e3283432dd3","volume":"23","author":"E Krishnan","year":"2011","unstructured":"Krishnan\u00a0E, Sokolove\u00a0J. Uric acid in heart disease: a\u00a0new C\u2011reactive protein? Curr Opin Rheumatol. 2011;23(2):174\u20137.","journal-title":"Curr Opin Rheumatol"},{"key":"1802_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1731503","author":"I Krecak","year":"2020","unstructured":"Krecak\u00a0I, Lucijanic\u00a0M, Gveric-Krecak\u00a0V, Durakovic\u00a0N. Hyperuricemia might promote thrombosis in essential thrombocythemia and polycythemia vera. Leuk Lymphoma. 2020; https:\/\/doi.org\/10.1080\/10428194.2020.1731503.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"1802_CR13","first-page":"1128","volume":"90","author":"J Thiele","year":"2005","unstructured":"Thiele\u00a0J, Kvasnicka\u00a0HM, Facchetti\u00a0F, Franco\u00a0V, van der Walt\u00a0J, Orazi\u00a0A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128\u201332.","journal-title":"Haematologica"},{"issue":"2","key":"1802_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.11613\/BM.2012.018","volume":"22","author":"M Lucijanic","year":"2012","unstructured":"Lucijanic\u00a0M, Petrovecki\u00a0M. Analysis of censored data. Biochem Med. 2012;22(2):151\u20135.","journal-title":"Biochem Med"},{"issue":"1","key":"1802_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.11613\/BM.2017.002","volume":"27","author":"M Lucijanic","year":"2017","unstructured":"Lucijanic\u00a0M, Skelin\u00a0M, Lucijanic\u00a0T. Survival analysis, more than meets the eye. Biochem Med. 2017;27(1):14\u20138.","journal-title":"Biochem Med"},{"issue":"1","key":"1802_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3325\/cmj.2016.57.77","volume":"57","author":"M Lucijanic","year":"2016","unstructured":"Lucijanic\u00a0M. Survival analysis in clinical practice: analyze your own data using an Excel workbook. Croat Med\u00a0J. 2016;57(1):77\u20139.","journal-title":"Croat Med J"},{"issue":"1","key":"1802_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/sj.leu.2404048","volume":"20","author":"F Cervantes","year":"2006","unstructured":"Cervantes\u00a0F, Alvarez-Larran\u00a0A, Arellano-Rodrigo\u00a0E, Granell\u00a0M, Domingo\u00a0A, Montserrat\u00a0E. Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a\u00a0series of 155\u00a0patients from a\u00a0single institution. Leukemia. 2006;20(1):55\u201360.","journal-title":"Leukemia"},{"issue":"10","key":"1802_CR18","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.3324\/haematol.2010.025064","volume":"95","author":"MA Elliott","year":"2010","unstructured":"Elliott\u00a0MA, Pardanani\u00a0A, Lasho\u00a0TL, Schwager\u00a0SM, Tefferi\u00a0A. Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. Haematologica. 2010;95(10):1788\u201391.","journal-title":"Haematologica"},{"issue":"4","key":"1802_CR19","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","volume":"115","author":"T Barbui","year":"2010","unstructured":"Barbui\u00a0T, Carobbio\u00a0A, Cervantes\u00a0F, et\u00a0al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115(4):778\u201382.","journal-title":"Blood"},{"issue":"9","key":"1802_CR20","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s00277-016-2712-0","volume":"95","author":"YQ Pei","year":"2016","unstructured":"Pei\u00a0YQ, Wu\u00a0Y, Wang\u00a0F, Cui\u00a0W. Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a\u00a0meta-analysis. Ann Hematol. 2016;95(9):1391\u20138.","journal-title":"Ann Hematol"},{"issue":"12","key":"1802_CR21","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1007\/s00277-020-04239-4","volume":"99","author":"M Lucijanic","year":"2020","unstructured":"Lucijanic\u00a0M, Galusic\u00a0D, Krecak\u00a0I, et\u00a0al. Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis. Ann Hematol. 2020;99(12):2779\u201385.","journal-title":"Ann Hematol"},{"issue":"3","key":"1802_CR22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s12185-020-02898-7","volume":"112","author":"I Kre\u010dak","year":"2020","unstructured":"Kre\u010dak\u00a0I, Holik\u00a0H, Martina\u00a0MP, Zekanovi\u0107\u00a0I, Coha\u00a0B, Gveri\u0107-Kre\u010dak\u00a0V. Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera. Int J Hematol. 2020;112(3):377\u201384. https:\/\/doi.org\/10.1007\/s12185-020-02898-7.","journal-title":"Int J Hematol"},{"issue":"5","key":"1802_CR23","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1097\/HJH.0000000000001980","volume":"37","author":"B De Becker","year":"2019","unstructured":"De Becker\u00a0B, Borghi\u00a0C, Burnier\u00a0M, van de Borne\u00a0P. Uric acid and hypertension: a\u00a0focused review and practical recommendations. J\u00a0Hypertens. 2019;37(5):878\u201383.","journal-title":"J Hypertens"},{"issue":"2","key":"1802_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11926-010-0094-1","volume":"12","author":"M Mazzali","year":"2010","unstructured":"Mazzali\u00a0M, Kanbay\u00a0M, Segal\u00a0MS, et\u00a0al. Uric acid and hypertension: cause or effect? Curr Rheumatol Rep. 2010;12(2):108\u201317.","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"1802_CR25","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1111\/j.1523-1755.2005.00273.x","volume":"67","author":"UM Khosla","year":"2005","unstructured":"Khosla\u00a0UM, Zharikov\u00a0S, Finch\u00a0JL, et\u00a0al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67(5):1739\u201342.","journal-title":"Kidney Int"},{"issue":"23","key":"1802_CR26","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1161\/CIRCULATIONAHA.106.651117","volume":"114","author":"J George","year":"2006","unstructured":"George\u00a0J, Carr\u00a0E, Davies\u00a0J, Belch\u00a0JJ, Struthers\u00a0A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114(23):2508\u201316.","journal-title":"Circulation"},{"issue":"3","key":"1802_CR27","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1161\/01.CIR.0000046448.26751.58","volume":"107","author":"S Guthikonda","year":"2003","unstructured":"Guthikonda\u00a0S, Sinkey\u00a0C, Barenz\u00a0T, Haynes\u00a0WG. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation. 2003;107(3):416\u201321.","journal-title":"Circulation"},{"issue":"3","key":"1802_CR28","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1161\/01.HYP.35.3.746","volume":"35","author":"R Butler","year":"2000","unstructured":"Butler\u00a0R, Morris\u00a0AD, Belch\u00a0JJ, Hill\u00a0A, Struthers\u00a0AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension. 2000;35(3):746\u201351.","journal-title":"Hypertension"},{"issue":"6","key":"1802_CR29","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1161\/ATVBAHA.117.309128","volume":"37","author":"R Spiga","year":"2017","unstructured":"Spiga\u00a0R, Marini\u00a0MA, Mancuso\u00a0E, et al. Uric acid is associated with inflammatory biomarkers and induces inflammation via activating the NF-kappaB signaling pathway in hepG2 cells. Arterioscler Thromb Vasc Biol. 2017;37(6):1241\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-020-01802-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-020-01802-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-020-01802-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T14:27:49Z","timestamp":1645194469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-020-01802-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":29,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1802"],"URL":"https:\/\/doi.org\/10.1007\/s00508-020-01802-x","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,19]]},"assertion":[{"value":"12 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"M.\u00a0Lucijanic, I.\u00a0Krecak, D.\u00a0Galusic, M.\u00a0Sedinic, H.\u00a0Holik, V.\u00a0Perisa, M.\u00a0Moric Peric, I.\u00a0Zekanovic, T.\u00a0Stoos-Veic, V.\u00a0Pejsa, and R.\u00a0Kusec declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the institutional review boards. All subjects in whom molecular studies were performed provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}